{"title":"Yiqi Jianpi Kangai Decoction Enhances the Chemotherapy Effect by Inducing Apoptosis and Regulating Treg and Th17 Cells in Colorectal Cancer Mice Model with Spleen Qi Deficiency.","authors":"Qinsha Wang, Shichao Li, Yao Fan, Weidong Chen, Qingfeng Jiang, Xin Sun, Qijun Lv, Wusheng Li, Yingtian Jia","doi":"10.1177/2515690X241313097","DOIUrl":"10.1177/2515690X241313097","url":null,"abstract":"<p><strong>Background: </strong>Colorectal Cancer (CRC) is widely prevalent worldwide and its incidence is increasing. Chemotherapy is an important treatment method for colorectal cancer in addition to surgery, but it often causes physical and mental pain to patients due to its side effects. TCM emphasizes evidence-based treatment and a holistic concept, and the combination of TCM and chemotherapy can reduce chemotherapy side effects, improve chemotherapy efficacy, and enhance patients' immunity. Yiqi Jianpi Kangai Decoction (YQJP) has been used clinically to treat patients with advanced colorectal cancer and may improve their immune function and prognosis. However, its mechanism has not been elucidated.</p><p><strong>Objective: </strong>The study aims to explore the effect and mechanism of YQJP on enhancing the therapeutic effect of chemotherapy on spleen qi deficiency type CRC mice.</p><p><strong>Methods: </strong>We used HPLC/MS to characterize the active substance components in YQJP. We established the spleen qi deficiency model induced by using the compound methods of diarrhea of bitter and cold, starvation, and full and excessive labor. and then inoculated CT-26 mouse colon cancer cells subcutaneously to establish the CRC Mice. We also evaluated the efficacy and mechanism of YQJP by using oral Yiqi Jianpi Kangai Decoction combined with an intraperitoneal injection of chemotherapeutic drugs (FOLFOX regimen). We evaluated the efficacy and safety of YQJP by observing the general condition (body weight, tumor size, food intake, hair condition, stool condition), HE staining, blood routine, and organ index of the mice. The expression of CD8<sup>+</sup>, CD4<sup>+</sup> T cells, Th17 cells, and Treg cells in the tumor and spleen were detected by flow cytometry, and the levels of IL-17, IL-10, IFN-γ and TGF-β in the tumor were detected by ELISA; the expression of Ki-67, PCNA, RORγt and FOXP3 proteins in the tumor was detected by immunohistochemistry.</p><p><strong>Results: </strong>YQJP contains 7 herbal compounds, which can effectively improve body weight, spleen condition, and bone marrow suppression in tumor-bearing mice inhibit tumor growth, and do not damage tissues and organs, which initially confirmed the anti-cancer effect and safety of YQJP. Further experiments showed that YQJP could elevate the proportion of CD8<sup>+</sup>, CD4<sup>+</sup> T cells in the spleen, increase the proportion of Th17 cells in the tumor tissue of mice, and decrease the level of Treg cells. It can inhibit the expression of Ki-67 and PCNA. Meanwhile, it promotes the expression of IL-17 and IFN-γ and inhibits the expression of IL-10 and TGF-β. In addition, it can reduce the relative expression of FOXP3 and increase the relative expression of RORγt.</p><p><strong>Conclusion: </strong>The combination of YQJP with chemotherapy had the effect of tumor suppression and enhanced chemotherapeutic efficacy in the spleen qi deficiency CRC mice. The related mechanism may be r","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":"30 ","pages":"2515690X241313097"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hui Wang, Yu Du, Tong Chen, Zheng-Huan Mao, Jia-Yu Xu, Li Ding, Wen-Cong Ruan, Hai-Feng Li
{"title":"Body Acupuncture Conjunction with Rehabilitation for Upper Limb Improves Motor Functions in Children with Spastic Hemiplegic Cerebral Palsy: A Pilot Study.","authors":"Hui Wang, Yu Du, Tong Chen, Zheng-Huan Mao, Jia-Yu Xu, Li Ding, Wen-Cong Ruan, Hai-Feng Li","doi":"10.1177/2515690X251317438","DOIUrl":"10.1177/2515690X251317438","url":null,"abstract":"<p><strong>Objective: </strong>Aimed to investigate the effectiveness of body acupuncture on motor function of the upper limb in children with spastic hemiplegic cerebral palsy (CP) conjunction with rehabilitation program.</p><p><strong>Design: </strong>The study is a randomized controlled experimental trial. Children with CP were randomly divided into the acupuncture group (body acupuncture with rehabilitation) and the rehabilitation group. The muscle volume difference between the upper limbs, the fine motor scores of the Peabody developmental motor scale-2 (PDMS-FM) and the surface electromyography (SEMG) parameter-root mean square (RMS)-on upper limb muscles (biceps brachii, radial wrist extensors and pronator teres) of both groups were measured before and after a 12-week treatment.</p><p><strong>Results: </strong>37 children completed the study. In the two groups, differences in muscle volume, PDMS-FM scores and RMS values (biceps brachii, radial wrist extensors and pronator teres) were significantly improved, except PDMS-FM score difference and difference of RMS values (biceps brachii, radial wrist extensors and pronator teres) between the upper limbs in the rehabilitation group. Comparison post-treatment/pre-treatment change for two groups showed significant difference in affected upper limb PDMS-FM total score, PDMS-FM score difference between the upper limbs, affected upper limb RMS values and RMS value difference between the upper limbs in favor of the acupuncture group.</p><p><strong>Conclusion: </strong>Our preliminary research indicates that body acupuncture therapy combined with rehabilitation may be more effective than rehabilitation alone, further improving muscle strength of affected upper limb and possibility of bimanual coordination in children with spastic hemiplegic CP.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":"30 ","pages":"2515690X251317438"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Akashlal M, Pratibha P Nair, Devi R Nair, Azeem Ahmad, B Chandrasekhararao, D Sudhakar, Srikanth Narayanam, Rabinarayan Acharya
{"title":"A Systematic Review on Safety and Efficacy of Ayurvedic Interventions in Hemiplegia (<i>Pakshaghata</i>).","authors":"Akashlal M, Pratibha P Nair, Devi R Nair, Azeem Ahmad, B Chandrasekhararao, D Sudhakar, Srikanth Narayanam, Rabinarayan Acharya","doi":"10.1177/2515690X241304523","DOIUrl":"https://doi.org/10.1177/2515690X241304523","url":null,"abstract":"<p><p>The study's objective is to conduct a comprehensive systematic review for assessing the safety and efficacy of Ayurvedic interventions in managing hemiplegia/Pakshaghata. The study involved a search across multiple online databases and online clinical trial registries. Additionally, major Ayurveda postgraduate institutes were contacted to acquire unpublished trial data related to hemiplegia/Pakshaghata. The review covered articles published until July 2023. Two reviewers independently performed data extraction and risk of bias assessment. The risk of bias assessment utilised the RoB 2 tool for randomised trials and the ROBINS-I tool for non-randomised trials. The screening process identified 28 articles from online databases and two dissertations from online repositories. However, practical challenges prevented access to grey literature from Ayurveda institutes. The 30 studies selected for this review, comprises nine randomised controlled trials (RCTs), eight non-randomised comparative trials, and thirteen pre-post studies. Quantitative analysis was unfeasible due to inadequate studies, leading to a qualitative analysis. All studies, except one, exhibited substantial bias upon risk of bias assessment. Moreover, most studies demonstrated methodological weaknesses attributed to a lack of masking, improper sampling techniques, non-validated outcome measurement tools, inadequate follow-up procedures, and confounding factors. The trials frequently did not document safety parameters, adverse events (AE), and adverse drug reactions (ADR). Current review could not definitively establish the efficacy and safety of Ayurvedic interventions in hemiplegia/Pakshaghata. Hence, the authors strongly advocate for good quality research incorporating proper methodology.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":"30 ","pages":"2515690X241304523"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluating the Hypoglycemic Efficacy and Quality Assurance of Ya That Opchoei Mixture.","authors":"Thaweesak Juengwatanatrakul, Kusuma Jitsaeng, Rawiwun Kaewamatawong","doi":"10.1177/2515690X251324810","DOIUrl":"10.1177/2515690X251324810","url":null,"abstract":"<p><p>Diabetes mellitus, diagnosed as Madhumeho (sweet urine) in Thai traditional medicine, is believed to stem from imbalanced life elements. Ya That Opchoei mixture (YTO), a polyherbal mixture, is used to treat its symptoms. This study assessed the hypoglycemic potential of YTO and conducted qualitative and quantitative analyses of its bioactive constituents. YTO significantly inhibited <i>α</i>-glucosidase at IC<sub>50</sub> 0.05 ± 0.00 mg/mL and <i>α</i>-amylase activities at IC<sub>50</sub> 0.04±mg/mL. YTO at concentrations of 2.22 mg/mL significantly increased C-peptide secretion and stimulated glucose uptake. Liquid chromatography-mass spectrometry revealed constituents from <i>Amomum testaceum</i>, <i>Cinnamomum bejolghota</i>, <i>C. burmanii</i>, <i>Syzygium aromaticum</i>, and <i>Glycyrrhiza glabra</i>. High-performance liquid chromatography enabled quantification of bioactive compounds, including glycyrrhizic acid, eugenol, cinnamic acid, cinnamaldehyde, and coumarin. The coumarin content in 100 mL YTO was within the tolerable daily intake set by the European Food Safety Authority. This study confirms the hypoglycemic potential of YTO and presents its quality control process for safety assurance.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":"30 ","pages":"2515690X251324810"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yao-Chien Wang, Yu-An Hsu, Sheng-Chun Lin, Li-Shan Chien, Jamie Jiin Yi Chen, Ming Yen Wu, Hui-Ju Lin, Chih-Sheng Chen, Yi-Qi Huang, Yu-Chi Tsai, Lei Wan
{"title":"Radish Seed Exerts Anti-Diabetic and Obesity-Reducing Effects in Mice by Promoting the Activation of Uncoupling Protein 1 and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α.","authors":"Yao-Chien Wang, Yu-An Hsu, Sheng-Chun Lin, Li-Shan Chien, Jamie Jiin Yi Chen, Ming Yen Wu, Hui-Ju Lin, Chih-Sheng Chen, Yi-Qi Huang, Yu-Chi Tsai, Lei Wan","doi":"10.1177/2515690X251316760","DOIUrl":"10.1177/2515690X251316760","url":null,"abstract":"<p><p>Obesity is primarily due to excessive energy intake and lipid accumulation, leading to type 2 diabetes. Studies showed radish seed extract (RSE) can impede weight gain in mice, but the mechanism was unclear. We hypothesized that RSE inhibits obesity by stimulating adipocyte browning. Radish seeds were water-extracted, yielding a sulforaphene (SE) concentration of 1.381 ± 0.005 mg/g RSE. In 3T3-L1 adipocyte differentiation experiments, RSE and SE increased the expression of beige adipocyte markers uncoupling protein 1 (UCP1) and peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC1α). In C57BL/6 mice, RSE and SE mitigated weight increase, averted fatty liver, and diminished fat accumulation. In the adipose tissue, we also noted the enhanced browning of white adipocytes through elevated expression of UCP1 and PGC1α. Increased mitochondrial numbers in treated adipocytes supported this effect. Additionally, RSE and SE improved glucose homeostasis and insulin sensitivity in high-fat diet-fed mice, indicating RSE's potential to prevent obesity and diabetes by enhancing adipocyte thermogenesis.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":"30 ","pages":"2515690X251316760"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Samah Hachem, Miriam Al Battal, Hoda Dakdouk, Dania El Natour, Jamilah Borjac
{"title":"Anti-Inflammatory and Antioxidant Effects of <i>Gundelia tournefortii</i> Aqueous Extract on the Liver and Kidney of PCOS Mice.","authors":"Samah Hachem, Miriam Al Battal, Hoda Dakdouk, Dania El Natour, Jamilah Borjac","doi":"10.1177/2515690X241304519","DOIUrl":"10.1177/2515690X241304519","url":null,"abstract":"<p><strong>Background: </strong>Polycystic Ovarian Syndrome (PCOS) is an endocrine disorder associated with increased risk of kidney and liver damage. Current treatments have shown contradictory outcomes, and their long-term use causes unwanted side effects. <i>G. tournefortii</i> could serve as a complementary medicine to current PCOS treatments.</p><p><strong>Purpose: </strong>This study evaluates the effect of <i>G. tournefortii</i> in alleviating liver and kidney damage induced by PCOS via the regulation of oxidative stress pathways.</p><p><strong>Study design: </strong>PCOS was induced in female Balb/c mice using dehydroepiandrosterone over 21 days. They included a Sham group, a Vehicle group, a group treated with the extract only, and an untreated PCOS mice group. Positive Controls were treated with Metformin. The other PCOS groups were either co-treated while inducing PCOS or treated with the extract post-disease induction.</p><p><strong>Methods: </strong>Histological analysis was performed. Serum liver and kidney biochemical markers, levels of oxidative stress, and two pro-inflammatory markers were measured. NLRP3 and its associated genes (caspase-1 and ASC) gene expression was assessed.</p><p><strong>Results: </strong>The extract restored normal kidney and liver histology post-PCOS induction. It decreased ALT and AST levels by 50% and the oxidant marker malondialdehyde (MDA) by 65% (<i>P</i> < .05). Superoxide dismutase (SOD)/catalase (CAT) activities were normalized in PCOS treated group. IL-1β/TNF-α significantly decreased (80% and 68%, respectively, <i>P</i> < .05) in the post-treated group. NLRP3 genes decreased in kidney tissues post-treatment with <i>G. tournefortii</i> extract.</p><p><strong>Conclusion: </strong><i>G. tournefortii</i> reduced oxidative stress by modifying the ASC/caspase-1/IL-1β signaling pathway, thus protecting livers and kidneys highlighting the herb as a potential preventative and complementary agent in mitigating PCOS associated damage.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":"30 ","pages":"2515690X241304519"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wei Su, Han Chen, Die Hu, Bixing Ye, Weifeng Zhang, Guoxin Zhang, Xinmin Si, Xiaoying Zhou
{"title":"The Causal Role of Esophageal Cancer and Gut Microbiota: A Bidirectional Mendelian Randomization Study.","authors":"Wei Su, Han Chen, Die Hu, Bixing Ye, Weifeng Zhang, Guoxin Zhang, Xinmin Si, Xiaoying Zhou","doi":"10.1177/2515690X251324793","DOIUrl":"10.1177/2515690X251324793","url":null,"abstract":"<p><strong>Aims: </strong>Gut microbiota are reported to be associated with the incidence and prognosis of Esophageal cancer (EC) but their genetic association is unclear. We carried out a bidirectional MR analysis to assess the causal relationship between EC and gut microbiota from fecal samples.</p><p><strong>Methods: </strong>The microbiome genome-wide association studies (GWAS) data of 18,340 individuals provided by MiBioGen consortium and the EC GWAS data (740 esophageal cancers cases and 372 016 controls) provided by UK Biobank were respectively utilized as exposure and/or outcome data. Reliable single nucleotide polymorphisms (SNPs) were obtained after rigorous screening. A bidirectional Mendelian randomization (MR) analysis was conducted using the inverse-variance weighted (IVW) method. The sensitivity analyses including the MR-Egger method, weighted median, weighed mode and leave-one-out method were performed to examine the stability, heterogeneity and pleiotropy of the results.</p><p><strong>Results: </strong>Forward MR analysis revealed the increase in abundance of the microbial trait by each standard deviation was associated with a higher risk of EC (<i>Coprobacter</i> (OR = 1.001,95%CI = 1.000-1.002, <i>P </i>= .0281, FDR = 0.0424); <i>Ruminococcus1</i>(OR = 1.001,95%CI = 1.000-1.002, <i>P </i>= .0318, FDR = 0.0424); <i>Senegalimassilia</i> (OR = 1.002,95%CI = 1.000-1.003, <i>P </i>= .0062, FDR = 0.0372); <i>Veillonella</i> (OR = 1.001,95%CI = 1.000-1.002, <i>P </i>= .0182, FDR = 0.0372)) or a lower risk of EC (<i>Eubacterium oxidoreducens</i> (OR = 0.999, 95%CI = 0.998-1.000, <i>P </i>= .0379, <i>FDR </i>= 00 433); <i>Lachnospira</i> (OR = 0.998,95%CI = 0.996-1.000, <i>P </i>= .0186, <i>FDR </i>= 0.0372); Romboutsia (OR = 0.999,95%CI = 0.998-1.000, <i>P </i>= .0482, FDR = 0.0482); <i>Turicibacter</i> (OR = 0.999,95%CI = 0.998-1.000, <i>P </i>= .0133, FDR = 0.0372)). Reverse MR analysis showed that genetic liability to EC was also causally linked toincreased susceptibility of changes in the gut microbiome (genera <i>Eggerthella</i> (Beta = 37.63,95%CI = 4.76-70.50, <i>P </i>= .0248, FDR = 0.0331); <i>Coprococcus 2</i> (Beta = 23.90,95%CI = 1.65-46.15, <i>P </i>= .0353, FDR = 0.0353); <i>Christensenellaceae R.7</i> (Beta = 22.75,95%CI = 4.22-41.28, <i>P </i>= .0161, FDR = 0.0322); <i>Intestinimonas</i> (Beta = -33.24,95%CI = -54.90-11.58, <i>P </i>= .0026, <i>FDR </i>= 0.0104)).</p><p><strong>Conclusions: </strong>Our findings supported a bidirectionally causal relationship between gut microbiota and EC, implying the potential role of gut microbiota in preventing the occurrence and development of EC.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":"30 ","pages":"2515690X251324793"},"PeriodicalIF":3.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shabnam Salekzamani, Saman Baharomid, Sina Pakkhesal, Maryam Balafkandeh, Elnaz Gholipour-Khalili, Mahnaz Talebi, Sarvin Sanaie, Amirreza Naseri
{"title":"The Effects of Coffee/Caffeine in Patients with Multiple Sclerosis; A Systematic Review.","authors":"Shabnam Salekzamani, Saman Baharomid, Sina Pakkhesal, Maryam Balafkandeh, Elnaz Gholipour-Khalili, Mahnaz Talebi, Sarvin Sanaie, Amirreza Naseri","doi":"10.1177/2515690X241293114","DOIUrl":"10.1177/2515690X241293114","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. Caffeine, as the most widely consumed psychoactive substance, has been suggested to have potential effects on the clinical course and disability levels of MS patients. This study aimed to review the current evidence on the effects of coffee/caffeine in patients with MS.</p><p><strong>Methods: </strong>This study followed the Joanna Briggs Institute (JBI) Manual for Evidence Synthesis and PRISMA 2020 statement. Clinical evidence regarding the effects of caffeine/coffee in MS patients was considered. A systematic search was performed in PubMed, Scopus, Web of Science, and Embase in October 2023, and updated via handsearching in March 2024. JBI's critical appraisal tools were utilized to scrutinize the risk of bias.</p><p><strong>Results: </strong>Out of 297 screened records, eight studies were eventually found to meet our inclusion criteria. The sample size of the studies varied between 12 and 1372 and the study designs were retrospective cohort, RCT, single-blind crossover trial, single-arm pilot study (each one study), and cross-sectional (four studies). No significant association between the level of disability and coffee/caffeine intake has been reported, although it was reported to be associated with cognitive improvements.</p><p><strong>Discussion: </strong>Evidence indicates an association between coffee/caffeine consumption, and improved cognitive outcomes in patients with MS, while there is no considerable relationship with the disease disability. Considering the limitations of the evidence, such as the small number of studies, and great diversity in study designs, the findings of this study should translate to clinical practice with caution.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":"29 ","pages":"2515690X241293114"},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evidence of Potential Natural Products for the Management of Hypertrophic Scars.","authors":"Thunyaluk Meetam, Apichai Angspatt, Pornanong Aramwit","doi":"10.1177/2515690X241271948","DOIUrl":"10.1177/2515690X241271948","url":null,"abstract":"<p><p>Hypertrophic scarring is an aberrant wound-healing response to reestablish dermal integrity after an injury and can cause significant abnormalities in physical, aesthetic, functional, and psychological symptoms, impacting the patient's quality of life. There is currently no gold standard for preventing and treating hypertrophic scars. Therefore, many researchers have attempted to search for antihypertrophic scar agents with greater efficacy and fewer side effects. Natural therapeutics are becoming attractive as potential alternative anti-scarring agents because of their high efficacy, safety, biocompatibility, low cost, and easy accessibility. This review demonstrates various kinds of natural product-based therapeutics, including onion, vitamin E, Gotu kola, green tea, resveratrol, emodin, curcumin, and others, in terms of their mechanisms of action, evidence of efficacy and safety, advantages, and disadvantages when used as anti-scarring agents. We reviewed the literature based on data from in vitro, in vivo, and clinical trials. A total of 23 clinical trials were identified in this review; most clinical trials were ranked as having uncertain results (level of evidence 2b; n = 16). Although these natural products showed beneficial effects in both in vitro and in vivo studies of potential anti-scarring agents, there was limited clinical evidence to support their efficacy due to the limited quality of the studies, with individual flaws including small sample sizes, poor randomization, and blinding, and short follow-up durations. More robust and well-designed clinical trials with large-scale and prolonged follow-up durations are required to clarify the benefits and risks of these agents.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":"29 ","pages":"2515690X241271948"},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11359448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shu Dong Md, Panling Xu Md, Peiwen Yang Md, Juying Jiao Md, Chien-Shan Cheng Md PhD, Lianyu Chen Md PhD
{"title":"\"Huanglianjiedu Decoction\" Against Pancreatic Adenocarcinoma Proliferation of by Downregulating the PI3K/AKT/mTOR and MAPK/ERK1/2 Signaling Pathways.","authors":"Shu Dong Md, Panling Xu Md, Peiwen Yang Md, Juying Jiao Md, Chien-Shan Cheng Md PhD, Lianyu Chen Md PhD","doi":"10.1177/2515690X241291381","DOIUrl":"https://doi.org/10.1177/2515690X241291381","url":null,"abstract":"<p><strong>Background: </strong>Huanglianjiedu decoction (HLJDD) is a classical Traditional Chinese Medicine (TCM) prescription with thousand years of clinical use against various malignancies, including pancreatic adenocarcinoma (PAAD). However, its potential bioactive component and molecular mechanism remains unclear.</p><p><strong>Aims: </strong>This study is to inspect the HLJDD mechanisms of action against PAAD via integrated computational and pharmacochemistry strategy, <i>in vivo</i> and <i>in vitro</i> experiments to validate associated targets and pathways.</p><p><strong>Methods: </strong>A PAAD xenograft model was established by subcutaneous injecting Panc02 cells into C57BL/6 mice. Ultra-high performance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS) was engaged to determine constituents of HLJDD and assessed for pharmacokinetic scheme using the TCM Systems Pharmacology Platform (TCM-SP). Differentially expressed genes (DEGs) of PAAD was retrieved from the transcriptome dataset GSE43795, followed by recognizing overlapping targets the oncogenes and target genes of PAAD and HLJDD, respectively. Putative signaling pathways of HLJDD in treating PAAD were enriched using KEGG and GO analyses. The anti-PAAD effects of HLJDD was assessed <i>in vivo</i> and <i>in vitro</i>, besides, the potential mechanism was validated using immunoblotting and immunohistochemical assays.</p><p><strong>Results: </strong>HLJDD significantly suppressed the growth of transplanted PAAD tumors, constrained PAAD progression, and induced apoptosis and S-phase arrest. Seventy-five active components meeting the drug-likeness criteria and 278 target genes of HLJDD were identified. KEGG analysis indicated that the top three enriched pathways were cancer, AGE-RAGE signaling, and IL-17 signaling pathways. Disease enrichment analysis highlighted immune, pharmacological, and cancer-related diseases as the top three categories. A total of 47 potential target genes were identified. Immunoblotting revealed that HLJDD inhibited PI3K and MAPK-related signaling pathways, while immunohistochemical staining confirmed that HLJDD suppressed the expression of phosphorylated MAPK and ERK1/2.</p><p><strong>Conclusion: </strong>HLJDD inhibited PAAD <i>in vitro</i> and <i>in vivo</i> via the modulation of multiple mechanisms, including regulation of PI3K/AKT/mTOR and MAPK/ERK1/2 signaling pathways.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":"29 ","pages":"2515690X241291381"},"PeriodicalIF":3.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}